The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000681358
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
1/05/2026
Date registered
Help: Date registered
5/06/2026
Date last updated
Help: Date last updated
5/06/2026
Date data sharing statement initially provided
Help: Data sharing statement date
5/06/2026
Type of registration
Help: Type of registration
Retrospectively registered

Titles & IDs
Public title
MULTI-ANALYTE: Proof-of-Concept Study in healthy humans testing wearable monitoring patch for measuring multiple analytes in the body
Scientific title
A Proof-of-Concept Study Evaluating Biomarker Monitoring Patches for Creatine/Creatinine, Phenylalanine, and Tryptophan in Healthy Adults.
Additional trial identifiers [1] 317165 0
Nil.
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Sepsis 341747 0
Condition category
Condition code
Infection 337819 337819 0 0
Other infectious diseases

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
This is an exploratory, proof-of-concept, open-label study conducted in three independent cohorts (creatine/creatinine, phenylalanine, and tryptophan). This study will explore the Nutromics Sensor Device to measure the multiple different analytes in different cohorts. These patches will be applied on participant's upper arms. These patches contain microneedles that are inserted through the skin into the interstitial fluid layer that will measure the analytes mentioned above.

participants will receive a single oral bolus of the assigned supplement relative to the analyte tested (cohort-specific):
• Cohort 1: Oral bolus 10.0 grams Creatine ethyl ester
• Cohort 2: Oral bolus 5.0 grams Phenylalanine
• Cohort 3: Oral bolus 100mg/kg up to 6g Tryptophan

All supplements come in the form of a powder, that is created as a solution with water. All participants will be required to consume the supplement solution with oversight of the clinical study team to ensure that the oral dose has been completely administered.

Allocation is non-randomised. Participants are assigned to one of three cohorts based on (a) cohort-specific eligibility criteria and (b) participant availability relative to the cohort visit schedule. Interim data reviews after the first 7-10 participants may be split up equally across the 3 different cohorts, followed by the next 7-10 participants also equally split across 3 cohorts.

Participants will attend a screening visit at the clinic site for informed consent and eligibility assessments.
On the treatment day, participants will arrive to the clinic site for scheduled procedures where monitoring patches will be applied to begin, followed by a 2-hour burn-in period (2-hour wait period). Baseline blood samples will then be collected prior to oral administration of the assigned analyte (cohort-dependent: creatine, phenylalanine or tryptophan).
Serial blood samples will be collected over a 12-hour period post-dose to capture analyte kinetics. These blood samples will then be collected at predefined timepoints such as pre-dose (endogenous measurement) and at 1 hour (±15 min), 2 hours (±15 min), 4 hours (±15 min), 5.5 hours (±15 min), 7 hours (±30 min), 9 hours (±30 min) and 24 hours(±1 hour) post dose.
Participants will then continue patch wear at home overnight.
At approximately 24 hours post-application, participants will return for final blood collection (safety blood sample and blood sample of target analyte) and patch removal.
Intervention code [1] 333938 0
Diagnosis / Prognosis
Intervention code [2] 334191 0
Treatment: Devices
Description of the comparator or control
Serial blood sample results collected during the intervention will be used as the comparator.

Serial blood samples will be collected over a 12-hour period post-dose to capture analyte kinetics. These blood samples will then be collected at predefined timepoints such as pre-dose (endogenous measurement) and at 1 hour (±15 min), 2 hours (±15 min), 4 hours (±15 min), 5.5 hours (±15 min), 7 hours (±30 min), 9 hours (±30 min) and 24 hours(±1 hour) post dose.
Control group
Active

Outcomes
Primary outcome [1] 345279 0
Change in patch electrochemical signals from baseline, following oral administration of target analyte for each cohort. The electrochemical signals are raw analyte-specific data collected via E-AB biosensor mechanism (from the microneedles).
Timepoint [1] 345279 0
Continuous from patch application (before dose) through to the following day (24-hours).
Secondary outcome [1] 461168 0
Accuracy of Nutromics Sensor Device in measuring creatinine blood concentration compared to blood serum sample collection.
Timepoint [1] 461168 0
Pre-dose (endogenous measurement) and at 1 hour (±15 min), 2 hours (±15 min), 4 hours (±15 min), 5.5 hours (±15 min), 7 hours (±30 min), 9 hours (±30 min) and 24 hours(±1 hour) post dose.
Secondary outcome [2] 461769 0
Accuracy of Nutromics Sensor Device in measuring tryptophan blood concentration compared to blood serum sample collection.
Timepoint [2] 461769 0
Pre-dose (endogenous measurement) and at 1 hour (±15 min), 2 hours (±15 min), 4 hours (±15 min), 5.5 hours (±15 min), 7 hours (±30 min), 9 hours (±30 min) and 24 hours(±1 hour) post dose.
Secondary outcome [3] 461770 0
Accuracy of Nutromics Sensor Device in measuring Phenylalanine blood concentration compared to blood serum sample collection.
Timepoint [3] 461770 0
Pre-dose (endogenous measurement) and at 1 hour (±15 min), 2 hours (±15 min), 4 hours (±15 min), 5.5 hours (±15 min), 7 hours (±30 min), 9 hours (±30 min) and 24 hours(±1 hour) post dose.
Secondary outcome [4] 461772 0
To evaluate device-to-device reproducibility across multiple patches
Timepoint [4] 461772 0
Device application time, 3-hours post device application (burn-in period/calibrated baseline period), dose time, 1 hour (±15 min), 2 hours (±15 min), 4 hours (±15 min), 5.5 hours (±15 min), 7 hours (±30 min), 9 hours (±30 min) and 24 hours(±1 hour) post dose and device removal time.

Eligibility
Key inclusion criteria
1. Age 18–60 years.
2. Healthy individuals without any disease, syndrome, or significant acute or chronic medical illness, as determined by the Study Investigators.
3. No clinically significant abnormalities in vital signs, serum biochemistry, haematology, or other screening assessments that would contraindicate participation. Any known disorders that impact the metabolism of the oral consumption of each supplement such as:
- For creatine - participants with known kidney issues.
- For phenylalanine - metabolic or neurological conditions such as 'Phenylketonuria'.
- For Tryptophan - any disorders that affect serotonin production and participants that are taking any medications such as anti-depressants or migraine medications.
4. Normal renal function, as determined by the Study Investigators, including estimated creatinine clearance or eGFR within the protocol-defined acceptable range.
5. No known liver disease.
6. No known metabolic disease or disorder that may affect creatine, phenylalanine, tryptophan, or related biomarker levels.
7. Female participants of childbearing potential must have a negative pregnancy test at Screening and prior to dosing on the treatment day.
8. Participants must be willing and able to comply with study procedures, including patch application, serial blood sampling, oral analyte administration, overnight patch wear, and return for the 24-hour visit.
Minimum age
18 Years
Maximum age
60 Years
Sex
Both males and females
Healthy volunteers
Yes
Key exclusion criteria
1. Pregnancy, planned pregnancy during the study period, or breastfeeding.
2. Known history of renal impairment, liver disease, or metabolic disease.
3. History of migraine or recurrent migraine-type headaches.
4. Current or past co-morbid mental health condition that, in the opinion of the Study Investigators, may increase participant risk or interfere with study participation or interpretation of results.
5. Use of concomitant medications or supplements known to increase the risk of serotonin syndrome or affect serotonin pathways, including but not limited to:
a) SSRIs (Selective Serotonin Reuptake Inhibitors)
b) SNRIs (Serotonin Norephedrine Reuptake Inhibitors)
c) MAOIs (Monoamine Oxidase Inhibitors)
d) Triptans
e) Tramadol
f) St John’s Wort
6. Current or recent use of MDMA or other illicit drugs that, in the opinion of the Study Investigators, may increase participant risk or interfere with study outcomes.
7. Use of medications or supplements that may affect creatine, phenylalanine, tryptophan, or related analyte levels, unless deemed acceptable by the Study Investigators.
8. History of allergic reactions to adhesives, metals, plastics, or device components.
9. Skin conditions, scars, tattoos, markings, or other factors at the intended patch application site that may interfere with device placement, adhesion, or skin assessment.
10. Significant history of fainting, vasovagal reactions, or poor tolerance of blood draws.
11. Participation in another clinical trial within the last 30 days.
12. Inability to attend scheduled study visits or comply with study requirements.
13. Employee of Nutromics Operations Pty Ltd.
14. Any other condition that, in the opinion of the Principal Investigator or Study Investigators, would make participation not in the best interest of the participant or may compromise study integrity.

Study design
Purpose of the study
Diagnosis
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Not Applicable
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC

Funding & Sponsors
Funding source category [1] 321751 0
Commercial sector/Industry
Name [1] 321751 0
Nutromics Operations Pty Ltd.
Country [1] 321751 0
Australia
Primary sponsor type
Commercial sector/Industry
Name
Nutromics Operations Pty Ltd.
Address
Country
Australia
Secondary sponsor category [1] 324590 0
None
Name [1] 324590 0
Address [1] 324590 0
Country [1] 324590 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320296 0
Nutromics Diagnostics HREC
Ethics committee address [1] 320296 0
Ethics committee country [1] 320296 0
Australia
Date submitted for ethics approval [1] 320296 0
05/05/2026
Approval date [1] 320296 0
22/05/2026
Ethics approval number [1] 320296 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 149998 0
Mr Robert McLeay
Address 149998 0
Nutromics, 420 Victoria Street, Brunswick 3056, VIC, Australia
Country 149998 0
Australia
Phone 149998 0
+61 421 979 896
Fax 149998 0
Email 149998 0
Contact person for public queries
Name 149999 0
Robert McLeay
Address 149999 0
Nutromics, 420 Victoria Street, Brunswick 3056, VIC, Australia
Country 149999 0
Australia
Phone 149999 0
+61 421 979 896
Fax 149999 0
Email 149999 0
Contact person for scientific queries
Name 150000 0
Robert McLeay
Address 150000 0
Nutromics, 420 Victoria Street, Brunswick 3056, VIC, Australia
Country 150000 0
Australia
Phone 150000 0
+61 421 979 896
Fax 150000 0
Email 150000 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.